China Gives Fusen Pharma Green Light for Traditional Chinese Drug Clinical Trial
Fusen Pharm (01652.HK): The clinical trial application for innovative traditional Chinese medicine class 1.1 drug "SY 617" has been accepted.
On July 12th, Gelonhui reported that Fusen Pharm (01652.HK) announced that its wholly-owned subsidiary, Jiaheng (Zhuhai Hengqin) Medical Technology Co., Ltd., has submitted a clinical trial application for its independently developed SY617 to the China National Medical Products Administration and has obtained acceptance. The function of SY617 is to disperse wind and detoxify, clear heat and eliminate dampness. It is used to treat wind-heat-dampness syndrome in the differentiation of epidemic influenza, with symptoms of fever, heavy head, sore throat, aversion to wind, cough, limb soreness, chest tightness, epigastric distension, red tongue with greasy coating or yellow coating, and slippery or rapid or floating pulse. According to Minet data, in 2022, respiratory system drug use.
Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
Hong Kong stock market concept tracking | Heavy policies supporting the development of innovative drugs are introduced! The industry is expected to enter the fast lane of development (with concept stocks).
On July 5th, the State Council's executive meeting discussed and deployed the work related to promoting high-quality development of the digital economy, and approved the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain.
FUSEN PHARM: SUPPLEMENTAL ANNOUNCEMENT TO THE 2023 CORPORATE GOVERNANCE REPORT
Fussen Pharmaceutical (01652): Application for marketing licensing of “enzalumide softgels” accepted
Fusen Pharmaceutical (01652) announced that Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of the group, developed...
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
Insider Buying: Fusen Pharmaceutical Executive Chairman Bought CN¥908k Of Shares
FUSEN PHARM: ANNUAL REPORT 2023
Forson Pharmaceutical (01652.HK): Application for marketing license for “Compound Potassium Hydrogen Phosphate Injection” was accepted
Gelonghui, April 23 | Forson Pharmaceutical (01652.HK) announced that the compound potassium hydrogen phosphate injection developed by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of the Group, has submitted a marketing application to the China National Drug Administration and has been accepted for the treatment of the following diseases: as a phosphorus supplement in complete parenteral nutritional therapy; it can also be used for hypophosphatemia caused by certain diseases. Phosphorus is involved in sugar phosphorylation in sugar metabolism, making up phospholipids in membrane components, and is an important component of RNA, DNA, and many coenzymes in cells. Phosphorus is also involved in energy storage, conversion, and body fluid buffering functions
Forson Pharmaceutical (01652) spent about HK$546,900 to buy back 648,000 shares on April 17
Forson Pharmaceutical (01652) announced that on April 17, 2024, it cost about HK$546,900 to buy back 64.8...
Forson Pharmaceuticals (01652.HK) spent HK$581,500 to buy back 676,000 shares on April 16
On April 16, Gelonghui | Forson Pharmaceutical (01652.HK) announced that it spent HK$581,500 to buy back 676,000 shares on April 16.
Fussen Pharmaceutical (01652.HK) plans to establish a limited partnership to explore diversified business development
Gelonghui, April 16, 丨 Fussen Pharmaceutical (01652.HK) announced that on April 16, 2024, Henan Fusen, an indirect wholly-owned subsidiary of the company (as limited partner A), entered into a limited partnership agreement with the general partner and limited partner B to establish a limited partnership. Henan Fusen's total capital commitment is RMB 85 million, which will be disbursed using the Group's internal resources. The limited partnership will engage in investment business and participate in investing in different potential pharmaceutical-related enterprises or projects. Qingdao Qiji Electronic Technology Co., Ltd. is a limited company established in China. Limited partner B is mainly engaged in corporate investment and equity
Fussen Pharmaceutical (01652):. The marketing application for “metformin englicin tablets (I)” was submitted and accepted
Zhitong Finance App News, Fussen Pharmaceutical (01652) announced that the “metformin englicin tablets (I)” developed by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of the Group, has submitted a marketing application to the China National Drug Administration and has been accepted for the treatment of the following diseases: This product is used in combination with diet control and exercise, and is suitable for adult patients with type 2 diabetes who are being treated with engagliflozin and metformin hydrochloride to improve blood sugar control in these patients. “Metformin Engagliptin Tablets (I)” is a compound preparation composed of metformin hydrochloride and engagliflozin. The pharmacological effects are as follows: 2
Fusen Pharmaceutical Posts Higher Loss in 2023
Fusen Pharmaceutical Company Limited (HKG:1652) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely
Fuson Pharmaceutical (01652) announced the 2023 annual results, shareholders should account for 36.277 million yuan, an increase of 4.83% year-on-year
Fussen Pharmaceutical (01652) announced results for the year ended December 31, 2023, and the group made profits during the period...
FUSEN PHARM: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Fussen Pharmaceutical (01652.HK) plans to hold a board meeting on March 28 to consider and approve the annual results
Glonghui, March 18, 丨 Fussen Pharmaceutical (01652.HK) announced that the board of directors will meet on March 28, 2024 (Thursday) to consider and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and to consider the payment of a final dividend (if any).
No Data